That patient series, although suggesting clinical efficacy of ICIs in non-ccRCC, included patients treated with many different immunotherapy agents and combinations, including combinations with anti-VEGF(R) and anti-CTLA4 therapy. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.